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Abstract: Dianthin enzymes belong to ribosome-inactivating proteins (RIPs) of type 1, i.e., they
only consist of a catalytic domain and do not have a cell binding moiety. Dianthin-30 is very
similar to saporin-S3 and saporin-S6, two RIPs often used to design targeted toxins for tumor
therapy and already tested in some clinical trials. Nevertheless, dianthin enzymes also exhibit
differences to saporin with regard to structure, efficacy, toxicity, immunogenicity and production by
heterologous expression. Some of the distinctions might make dianthin more suitable for targeted
tumor therapies than other RIPs. The present review provides an overview of the history of dianthin
discovery and illuminates its structure, function and role in targeted toxins. It further discusses the
option to increase the efficacy of dianthin by endosomal escape enhancers.
Keywords: dianthin; ribosome-inactivating protein; targeted toxin; immunotoxin; endosomal escape;
cancer therapy; Dianthus caryophyllus L.
Key Contribution: The present review provides an overview of the structure and function of dianthin
and its potential as an attractive weapon in the fight against cancer when fused or coupled to
tumor-specific ligands or antibodies.
1. Introduction
Dianthin is the name for three homologous toxins obtained from the clove pink
(Dianthus caryophyllus L.) and sweet William (Dianthus barbatus L.). It was first described by Stirpe
and colleagues [1] who isolated two proteins, dianthin-30 and dianthin-32, from the leaves of
D. caryophyllus L. Another protein, dianthin-29, was isolated by Prestle et al. from frozen leaf
material of D. barbatus L. [2]. The dianthin enzymes must not be confused with cyclic penta-,
hexa-, and hepta-peptides isolated from fringed pink (Dianthus superbus L.) and rainbow pink
(Dianthus chinensis L., Dianthus sinensis Link) designated as dianthin A and B [3], dianthin C, D, E,
and F [4], dianthin G and H [5,6] and dianthin I [7,8]. These cyclic peptides are not part of this review.
The dianthin enzymes are ribosome-inactivating proteins (RIPs), which are N-glycosidases
(EC 3.2.2.22) that release a particular adenine from the 28S ribosomal RNA of eukaryotic ribosomes
(at position 4324 referred to rat) and thus inactivate protein biosynthesis [9,10]. The concentration of
dianthin-30 and dianthin-32 that results in 50% inhibition (IC50) of the protein synthesis in a lysate
of rabbit reticulocytes was initially determined to be 0.31 nM and 0.11 nM, respectively [1]. The IC50
of dianthin-29 in a rabbit reticulocyte lysate was 1.5 nM [2]. Dianthin-29 was described to inhibit in
addition prokaryotic ribosomes. Further RIP genes were identified in D. chinensis L., exhibiting 79%
homology with the dianthin-30 gene [11]. Expression of the proteins in Escherichia coli failed, indicating
that the translational products of D. chinensis L. RIP genes also display toxic effects on prokaryotic
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ribosomes [11,12]. In contrast, dianthin-30 can be produced in E. coli with high yield [13,14], and other
RIPs similar to saporin-S6 from Saponaria officinalis L. and dianthin-30 were also inactive on bacterial
ribosomes [15].
Most of the known RIPs are produced by plants and can be mainly divided into two groups, type
1 RIPs that consist of a single A-chain representing catalytic activity, and type 2 RIPs that, in addition,
contain a B-chain with cell binding properties, as compiled by Schrot et al. [16] (Table 1). The fact
that type 1 RIPs reveal high cytotoxicity once inside the cell but only low cytotoxicity when located
outside the cell due to the missing cell binding domain makes them ideal candidates for targeted tumor
therapies as the toxin can be recombinantly fused or chemically coupled to tumor-specific ligands or
antibodies, which then mediate cellular uptake [17,18]. Therefore, type 1 RIPs such as saporin and
bouganin from Bougainvillea spectabilis Willd. have been investigated in a number of attempts as part of
targeted toxins in cancer therapy [19,20]. The present review provides an overview of the structure and
function of the type 1 RIP dianthin and its potential as an attractive weapon in the fight against cancer.
Table 1. List of dianthin enzymes and of other ribosome-inactivating proteins (RIPs) that are directly
compared to dianthins in this article. Data are obtained from the review composed by Schrot et al. [16]
except for saporin-S3 [21], crotin-3 [12] and ricin A-chain [22]. In some cases, RIPs described in this
review cannot be unequivocally assigned since the identity of that RIP was not fully clarified in the
corresponding publication.
RIP Type Plant Plant Source Molecular Mass (kDa)
dianthin-29 1 Dianthus barbatus L. leaves 29.0
dianthin-30 1 Dianthus caryophyllus L. leaves 29.5
dianthin-32 1 Dianthus caryophyllus L. leaves 31.7
saporin-S3 1 Saponaria officinalis L. seeds 28.6
saporin-S6 1 Saponaria officinalis L. seeds 28.6
saporin-S9 1 Saponaria officinalis L. seeds 28.5
saporin-R1 1 Saponaria officinalis L. roots 30.2
saporin-R2 1 Saponaria officinalis L. roots 30.9
PAP 1 1 Phytolacca americana L. leaves 29–30
PAP-S 1 1 Phytolacca americana L. seeds 30
PAP-R 1 1 Phytolacca americana L. roots 29.8
PD-S2 2 1 Phytolacca dioica L. seeds 29.6
gelonin 1 Gelonium multiflorum A.Juss seeds 30–31
bryodin 1 Bryonia dioica Jacq. roots 29
momordin 1 Momordica charantia L. seeds 31
momorcochin-S 1 Momordica cochinchinensisSpreng. seeds 30
trichokirin 1 Trichosanthes kirilowii Maxim. seeds 27
tritin 1 Triticum aestivum L. germ 30
crotin-3 1 Croton tiglium L. seeds n. a. 3
lychnin 1 Lychnis chalcedonica L. seeds 26.1
bouganin 1 Bougainvillea spectabilisWilld. leaves 26.2
colocin-1 1 Citrullus colocynthis (L.)Schrad. seeds 26.3
asparin 1 Asparagus officinalis L. seeds 29.8–30.5
barley RIP 1 Hordeum vulgare L. seeds 30
ricin A-chain 2 Ricinus communis L. seeds 32
ricin 2 Ricinus communis L. seeds 62.8
abrin-c 2 Abrus precatorius L. seeds 60.1–62.5
modeccin 2 Adenia digitata (Harv.) Engl. roots 57–63
viscumin 2 Viscum album L. leaves 115–125
volkensin 2 Adenia volkensii Harms roots 62
1 PAP, pokeweed antiviral protein; without suffix, the protein is obtained from leaves, suffixes -S and -R refer to
seeds and roots as source material, respectively. 2 PD-S2, Phytolacca dioica L. ribosome-inactivating protein number 2
from seeds. 3 n. a., information not available.
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2. Structure and Function
2.1. Purification and Expression of Dianthins
Dianthin-30 and dianthin-32 were first purified to homogeneity from the leaves of D. caryophyllus L.
by chromatography on carboxymethyl (CM-)cellulose, pH 6.5 [1]. The apparent molecular masses
determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) are 29,500
and 31,700 Da respectively, and origin for the naming [1]. Isoelectric focusing provided a single band
with a basic isoelectric point of 8.65 for dianthin-30 and 8.55 for dianthin-32, consistent with their
chromatographic behavior on CM-cellulose [23]. As determined by rocket immunoelectrophoresis
and by the ability to inhibit protein synthesis, dianthin-30 is present throughout the entire plant while
dianthin-32 is located only in leaves and growing shoots [24]. In the older parts of the plant, dianthin
contributes to 1% to 3% of the total extractable protein, whereas much less is present in the younger
parts [24].
The inhibitory activity of dianthin-30 and dianthin-32 was unchanged on pre-incubation at 37 ◦C
for 1 h in the presence of 1% 2-mercaptoethanol, or after freezing and thawing ten consecutive times,
or after keeping at 37 ◦C for 18 h, but was completely abolished by boiling for 20 min [1]. Freeze-dried
dianthin-32 retained full activity after solubilization while freeze-dried dianthin-30 was poorly soluble
and could not be tested [1].
Dianthin-29 was isolated and purified from frozen leaf material by affinity chromatography on
Blue 2 S-Sepharose and subsequent cation exchange chromatography on Mono S [2]. The apparent
molecular mass in SDS-PAGE is 29,000 Da [2].
Antibodies are helpful tools for the purification and detection of proteins. Strocchi et al. produced
a polyclonal rabbit antiserum against dianthin-32, which showed no cross-reactivity to lychnin from
Lychnis chalcedonica L. seeds, pokeweed antiviral protein from Phytolacca americana L. roots (PAP-R),
trichokirin from Trichosanthes kirilowii Maxim. seeds, and colocin-1 from Citrullus colocynthis (L.)
Schrad. seeds, week cross-reactivity to saporin-S6 from S. officinalis L. seeds, momordin from
Momordica charantia L. seeds and momorcochin-S from Momordica cochinchinensis (Lour.) Spreng.
seeds, and high cross-reactivity to bryodin-R from Bryonia dioica Jacq. roots [25]. This antiserum also
showed week or medium cross-reactivity with two RIPs isolated from leaves of Phytolacca dioica L. [26]
and RIPs isolated from the seeds of Saponaria ocymoides L., Vaccaria hispanica (Mill.) Rauschert [27]
and Basella rubra L. [28], and from the skinned fruit of Cucurbita moschata Duchesne [29]. A rabbit
immune antiserum raised against saporin-S6 did not cross-react with dianthin-32 [30]. Porro and
colleagues produced five different highly specific anti-dianthin-32 monoclonal antibodies that revealed
no cross-reactivity to momochin from M. cochinchinensis (Lour.) Spreng. and momordin, and two
of them also exhibited no cross-reactivity to saporin-S6, and gelonin from Gelonium multiflorum A.
Juss. However, all of them bound to dianthin-30, three of them even better than to dianthin-32 [31].
The affinity constants of these anti-dianthin monoclonal antibodies ranged between 1.7 × 1010 M–1
and 3.3 × 108 M–1 [31]. This shows that antibodies against dianthin often exhibit cross-reactivity to
RIPs from related plants and sometimes also to RIPs from unrelated plants, as observed for bryodin.
Interestingly, four serum samples collected from 17 persons who were employees in a research
laboratory and were in daily or in rare contact with RIPs contained specific immunoglobulin E (IgE)
against dianthin-30, gelonin, momordin, pokeweed antiviral protein from seeds (PAP-S), saporin, ricin
from Ricinus communis L. seeds and volkensin from Adenia volkensii Harms roots. In contrast, asparin
from Asparagus officinalis L. seeds and lychnin did not show any IgE binding. Strikingly, among the
other plant proteins, RIPs were exclusively recognized by IgE in immunoblots [32].
An important alternative to purification from natural sources is heterologous expression, however,
as RIPs inhibit eukaryotic ribosomes, expression in eukaryotic cells is excluded and even expression
in prokaryotes is sometimes not possible [11]. Nevertheless, dianthin-30 can be expressed in
bacterial systems. This was first described by Legname and colleagues who cloned the cDNA
encoding for dianthin-30 into the expression plasmid pKK 233.2 for protein production in E. coli strain
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JM109 [33]. The low amount of 20 µg/L recombinant protein was attributed to the inhibitory effect
of dianthin-30 on bacterial protein synthesis as it was shown before that the 23S rRNA of E. coli is
also a target for dianthin [34]. The yield was substantially increased to 10 mg/L by use of the pET11d
expression vector [14]. The authors expressed dianthin-30 and a deleted form (∆255–270), lacking the
putative 16 amino acids long pro-signal sequence, and determined the IC50 after purification via cation
exchange chromatography on Mono S to 0.29 nM, 0.37 nM, and 0.61 nM for dianthin-30 ∆255–270,
recombinant dianthin-30 and natural dianthin-30 respectively, measuring the inhibition of (14C)-leucine
incorporation into protein using a rabbit reticulocyte system [14]. Investigations by circular dichroism
spectroscopy indicated that the natural and the recombinant forms of dianthin-30 possess the same
secondary structure composition, accounting for anα+β type architecture [14]. A hexahistidine-tagged
dianthin-30 was expressed by Gilabert-Oriol and co-workers in pET11d using E. coli Rosetta 2(DE3)
pLysS and purified by Ni-nitrilotriacetic acid affinity chromatography eluting at 125 mM imidazole [13].
Mass spectrometry showed a single peak of 29,531 Da, indicating that the N-terminal methionine
is cleaved off in a bacterial post-translational modification [13]. Circular dichroism measurements
conducted after different storage times at −20 ◦C, 4 ◦C and 25 ◦C indicated that the protein stability
was not affected by the storage and the protein conformation remained the same. The protein was
stable up to 60 ◦C, where alterations of the structure commenced and achieved 50% denaturation at
66 ◦C and complete denaturation above 72 ◦C [13].
2.2. Primary and Spatial Structure of Dianthin-30 and Its Catalytic Center
Rabbit antibodies raised against dianthin-30 were used to identify a full-length dianthin precursor
cDNA clone from a lambda gt11 expression library [35]. The cDNA was 1153 base pairs in length and
encoded a precursor protein of 293 amino acid residues, of which the first 23 N-terminal amino acids
represented the signal sequence [35]. A comparison of the amino acid sequence of dianthin-30 revealed
83% homology with gypsophilin-S from the seeds of Gypsophila elegans M. Bieb. [36], 80% homology
with saporin-S6 [21] but only 17% with trichosanthin from T. kirilowii Maxim. and 20% with ricin
A-chain [35] (Figure 1). The C-terminal region contains an N-glycosylation site and shows homology to
a C-terminal propeptide present in several plant vacuolar proteins, such as wheat germ agglutinin and
barley lectin [35], which is necessary for proper sorting of the lectin to vacuoles [37]. The major sugars
observed at the glycosylation site are mannose, glucose and glucosamine for dianthin-32, and xylose
and glucose for dianthin-30 [23].
The three-dimensional structure of dianthin-30 was first predicted by a computer model applying
homology modeling on the basis of two known RIP structures from PAP and ricin A-chain [40].
The results demonstrate that, despite the similarity of the topology of the binding site, differences in
the electrostatic potential can account for experimentally observed differences in substrate recognition
and binding for the investigated RIPs [40]. Experimentally, the structure was independently solved
by Kurinov and colleagues for recombinantly expressed dianthin-30 (∆255–270) (Protein Data Bank
(PDB) IDs: 1LP8, 1LPC, 1LPD including complexes with adenyl-guanosine and cyclic AMP) at 1.7 Å
resolution [41], and by Fermani et al. for dianthin-30 purified from leaves of D. caryophyllus L. (PDB
ID: 1RL0) at 1.4 Å resolution [38,42]. Despite some varieties in the loop regions, the typical folding for
RIPs is conserved. The structures of dianthin-30 and saporin-S6 fit quite well and both show a protein
segment containing strands β7, β8 and β9 that is shorter than in other RIPs, however, the surface
electrostatic potential in the active site region distinguishes dianthin-30 from saporin-S6 [38] (Figure 2).
While the active site of saporin-S6 is characterized by a negative potential, dianthin-30 contains both
a negative potential and an extended positive region in the catalytic cavity [38] corroborating the
conclusions from the computer model on differences in the electrostatic potential for PAP and ricin
A-chain [40]. The four key residues in the catalytic center, Tyr-73, Tyr-121, Glu-177 and Arg-180,
are fully conserved in dianthin-30, saporin-S6, PAP, momordin, trichosanthin, lychnin, bouganin,
gelonin, bryodin and ricin A-chain [38,43,44]. Molecular modeling studies of the interactions of
dianthin-30 with a single-stranded RNA heptamer predicted a potent anti-human immunodeficiency
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virus (HIV-) RNA activity due to the unique surface topology and charge distribution in its 20 Å RNA
binding cleft. The estimated release was 352 ± 27 pmol adenine per microgram of RNA per hour [41].
Anti-HIV effects were observed for both dianthin-30 and dianthin-32 [45,46].Toxins 2019, 11, x FOR PEER REVIEW 5 of 25 
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Figure 1. Sequence alignment of the amino acids from dianthin-30 and dianthin-32 (as far as is known)
with other RIPs. Asterisks indicate fully conserved residues, colons show strongly similar and periods
show weakly similar residues. Highlighted amino acids are involved in the stabilization of the substrate
and in the catalysis [38]. Sequences were obtained from the UniProt Knowledgebase (UniProtKB), IDs
P24477, P24476, P20656, P93444, P33186, P33185, and P02879. The alignment was conducted with the
Clustal Omega tool [39].
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The catalytic activity of RIPs is mainly determined indirectly by in vitro translation assays using 
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Figure 2. Three-dimensional structure of (a) i t i -30 (Protein D ta Bank (PDB) ID: 1RL0) [38], (b)
saporin-S6 (PDB ID: 1QI7) [47], and (c) ricin A-c B ID: 1RTC) [48]. Th yellow residu s are the
conserved tyrosines in the active center highlig Figure 1, the right ones of them corresponding
to Tyr-73 of dianthin-30. Negative charged residues are depicted in red and positive residues in blue.
The glutamate and arginine of the catalytic pocket are designated with E and R, respectively. The active
site of dianthin-30 and saporin-S6 is easily accessible compared to ricin and other RIPs, and saporin-S6
is characterized by a more negative potential compared to dianthin-30 [38].
2.3. Enzymatic Activity and Biological Function
All RIPs mediate the release of adenine-4324 (number referred to rat) from the 28S rRNA of
eukaryotic ribosomes [9,10]. For dianthin-30 and dianthin-32, this was indirectly confirmed by
Reisbig and Bruland who demonstrated that ribosomes remain active when dianthin-treated 40S
subunits are combined with untreated 60S subunits but become inactive when treated 60S subunits
are combined with untreated 40S subunits [24]. The elease of adenine-4324 results in an aldehyde
radical at C1 o the ribose [9] an this aldehyde group inhibits the activiti s of the eukaryotic
elongation factor (eEF1A)-dependent aminoacyl-tRNA binding to the inactivated ribosome and
eEF1A-dependent guanosine-5’-triphosphatase (GTPase), but increases eEF2-dependent activity [49].
The catalytic activity of RIPs is mainly determined indirectly by in vitro translation assays using
rabbit reticulocyte lysate. Similar IC50 values between 0.133 nM and 0.61 nM were determined for
dianthin-30 in different studies (Table 2). Dianthin-30 and dianthin-32 also inhibited protein synthesis
in wheat germ extracts at 0.35–0.70 nM [24], while for ricin A-chain, a similar effect requires more
than 800 nM [50]. Moreover, ribosomes from several species are sensitive to their own RIPs, including
dianthin-32 [2], saporin [51], and PAP [52]. Notably, the enzymat activity must not be confused
with cyt toxicity as complete ricin possesses a cell binding domain (B-chain) whil dianthin can enter
cells only by chance. The enzymatic activity of dianthin-30 (∆255–270), which lacks the glycosylation
site, is comparable to that of full-length dianthin-30, indicating that the C-terminus and the sugar
residues are not involved in the N-glycosidase activity [14]. For saporin-S3 that shares (as saporin-S6)
80% homology with dianthin-30 [21], a complete loss of in vivo activity is observed in the double
mutant E176K, R179Q (KQ-mutant) [53], two residues of the catalytic center (residues 177 and 180 in
dianthin-30) [38]. Therefore, it can be expected that in dianthin-30, the analogous KQ-mutant will also
result in enzymatic activity loss.
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Table 2. Ribosome-inactivating potential of dianthin-30 and dianthin-32 as well as derivates thereof
directly compared to other RIPs in several studies. The experimental conditions partly vary substantially
between the different publications so that further method information in the source literature must
be taken into account for a more detailed comparison of the various RIPs. The activity was typically
quantitated by measuring inhibition of the protein synthesis in translation assays, e.g., by (14C)-leucine
incorporation or poly (U)-directed polymerization of (14C)-phenylalanine.






0.133 rabbit reticulocyte lysate [54]
0.18 rabbit reticulocyte lysate [21]
0.227 2 rabbit reticulocyte lysate [54]
0.29 1,2 rabbit reticulocyte lysate [14]
0.31 rabbit reticulocyte lysate [1]
0.37 2 rabbit reticulocyte lysate [14]
0.41 2 rabbit reticulocyte lysate [55]
0.61 rabbit reticulocyte lysate [14]
0.35–0.70 wheat germ extracts [24]
110 Leishmania infantum [56]
153 Trypanosoma bruceirhodesiense [56]
6478 Streptomyces lividans [12]
dianthin-30-anti-CD30 3
0.1 rabbit reticulocyte lysate [54]
1.054 2 rabbit reticulocyte lysate [54]
KFT25-dianthin-30 4 0.47 2 rabbit reticulocyte lysate [55]
pHA2-dianthin-30 4 0.53 2 rabbit reticulocyte lysate [55]
pJVE-dianthin-30 4 0.54 2 rabbit reticulocyte lysate [55]
dianthin-32
0.02 Saccharomyces cerevisiae [52]
0.11 rabbit reticulocyte lysate [1]
0.12 rabbit reticulocyte lysate [15]
0.12 rabbit reticulocyte lysate [57]
0.35–0.70 wheat germ extracts [24]
0.63 Nicotiana tabacum [52]
7 Acanthamoeba castellanii [58]
27 Leishmania infantum [56]
30 Tetrahymena pyriformis [58]
66 Trypanosoma bruceirhodesiense [56]
331 Streptomyces lividans [12]
991 Agrobacterium tumefaciens [15]
>1000 Escherichia coli [15]
dianthin-32-F(ab’)2 0.167 rabbit reticulocyte lysate [57]
saporin-S3 0.01–0.02 rabbit reticulocyte lysate [21]
saporin-S6
0.01–0.02 rabbit reticulocyte lysate [21]
0.033 rabbit reticulocyte lysate [57]
17 Acanthamoeba castellanii [58]
33 Leishmania infantum [56]
116 Trypanosoma bruceirhodesiense [56]
2630 Tetrahymena pyriformis [58]
>7133 Streptomyces lividans [12]




31 Leishmania infantum [56]
saporin-R1
0.86 rabbit reticulocyte lysate [15]
927 Escherichia coli [15]
>1000 Escherichia coli [15]
>1000 Agrobacterium tumefaciens [15]
saporin-R2
0.47 rabbit reticulocyte lysate [15]
423 Escherichia coli [15]
>1000 Escherichia coli [15]
>1000 Agrobacterium tumefaciens [15]
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Table 2. Cont.






0.14 Nicotiana tabacum [52]
0.29 Saccharomyces cerevisiae [52]
PAP-S
0.037 rabbit reticulocyte lysate [57]
17 Trypanosoma bruceirhodesiense [56]
21 Leishmania infantum [56]
1040 Streptomyces lividans [12]
1230 Acanthamoeba castellanii [58]
1570 Tetrahymena pyriformis [58]
PAP-S-F(ab’)2 0.41 rabbit reticulocyte lysate [57]
PAP-R
40 Trypanosoma bruceirhodesiense [56]
53 Leishmania infantum [56]
2005 Streptomyces lividans [12]
gelonin
0.4 rabbit reticulocyte lysate [57]
2590 Leishmania infantum [56]
3330 Trypanosoma bruceirhodesiense [56]
>3330 Tetrahymena pyriformis [58]
>3300 Acanthamoeba castellanii [58]
>11,000 Streptomyces lividans [12]
gelonin-F(ab’)2 6.2 rabbit reticulocyte lysate [57]
bryodin
0.12 rabbit reticulocyte lysate [57]
430 Acanthamoeba castellanii [58]
3330 Trypanosoma bruceirhodesiense [56]
>3330 Tetrahymena pyriformis [58]
>3330 Leishmania infantum [56]
>10,932 Streptomyces lividans [12]
bryodin-F(ab’)2 0.247 rabbit reticulocyte lysate [57]
momordin
0.06 rabbit reticulocyte lysate [57]
0.06 rabbit reticulocyte lysate [15]
72 Streptomyces lividans [12]
190 Escherichia coli [15]
190 Agrobacterium tumefaciens [15]
300 Tetrahymena pyriformis [58]
857 Escherichia coli [15]
1130 Acanthamoeba castellanii [58]
3330 Trypanosoma bruceirhodesiense [56]
>3330 Leishmania infantum [56]
momordin-F(ab’)2 0.44 rabbit reticulocyte lysate [57]
trichokirin
0.087 rabbit reticulocyte lysate [57]
1265 Trypanosoma bruceirhodesiense [56]
1747 Streptomyces lividans [12]
>3330 Leishmania infantum [56]
trichokirin-F(ab’)2 0.29 rabbit reticulocyte lysate [57]
tritin
22 Saccharomyces cerevisiae [52]
>2200 Nicotiana tabacum [52]
crotin-3
0.2 rabbit reticulocyte lysate [15]
13 Escherichia coli [15]
19 Streptomyces lividans [12]
40 Escherichia coli [15]
barley RIP
3 Saccharomyces cerevisiae [52]
1598 Trypanosoma bruceirhodesiense [56]
>2200 Nicotiana tabacum [52]
3330 Leishmania infantum [56]
4922 Streptomyces lividans [12]
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0.066 rabbit reticulocyte lysate [57]
0.17 Saccharomyces cerevisiae [52]
0.3 rabbit reticulocyte lysate [55]
21 Nicotiana tabacum [52]
800 wheat germ extracts [50]
ricin A-chain-F(ab’)2 0.078 rabbit reticulocyte lysate [57]
ricin
1030 Acanthamoeba castellanii [58]
>1700 Tetrahymena pyriformis, [58]
>1700 Trypanosoma bruceirhodesiense [56]
>1700 Leishmania infantum [56]
>3300 Streptomyces lividans [12]
abrin
5 Leishmania infantum [56]
49 Trypanosoma bruceirhodesiense [56]
100 Acanthamoeba castellanii [58]
>1700 Tetrahymena pyriformis [58]
modeccin
1700 Leishmania infantum [56]
>1700 Tetrahymena pyriformis, [58]
>1700 Acanthamoeba castellanii, [58]
>1700 Trypanosoma bruceirhodesiense [56]
viscumin
1700 Acanthamoeba castellanii [58]
>1700 Tetrahymena pyriformis, [58]
>1700 Trypanosoma bruceirhodesiense [56]
>1700 Leishmania infantum [56]
volkensin
830 Acanthamoeba castellanii [58]
1700 Leishmania infantum [56]
>1700 Tetrahymena pyriformis, [58]
>1700 Trypanosoma bruceirhodesiense [56]
>3300 Streptomyces lividans [12]
1 Dianthin-30 (∆255–270). 2 Recombinant protein. 3 CD, cluster of differentiation. 4 KFT25, N-terminus of protein G
of the vesicular stomatitis virus [59], pHA2, N-terminus of the HA2 hemagglutinin of influenza virus [60], pJVE,
proper name of a synthetic peptide [61].
As mentioned before, in several cases, RIPs can also inhibit prokaryotic ribosomes. Ferreras and
colleagues investigated the effects of 29 different type 1 and type 2 RIPs on polyuridylic acid-directed
polyphenylalanine synthesis carried out by purified ribosomes from Streptomyces lividans. Only five
of them exhibited an IC50 below 1 µM including dianthin-32 (331 nM) and as the most effective RIP,
crotin-3 (19 nM) from Croton tiglium L. seeds while dianthin-30 had an IC50 of 6.5 µM [12], indicating
that dianthin-30 is more suitable for heterologous expression in bacteria than dianthin-32.
Cenini and colleagues examined the effect of dianthin-32 on ribosomes of the ciliate
Tetrahymena pyriformis and the amoeba Acanthamoeba castellanii [58], and of both dianthin-30 and
dianthin-32 on ribosomes of the parasites Trypanosoma brucei rhodesiense and Leishmania infantum [56].
None of the type 2 RIPs ricin, abrin from Abrus precatorius L., modeccin from Adenia digitata (Harv.)
Engl., viscumin from Viscum album L., and volkensin, and the type 1 RIPs gelonin and bryodin had
any effect on phenylalanine polymerization by T. pyriformis ribosomes while PAP-S (IC50 = 1570 nM)
and saporin-S6 (IC50 = 2630 nM) had a weak effect, momordin a moderate effect (IC50 = 300 nM) and
dianthin-32 a strong effect (IC50 = 30 nM) [58]. The sensitivity of A. castellanii ribosomes to these RIPs
was higher than that of T. pyriformis RIPs but a strong effect was only observed for abrin (IC50 = 100 nM),
saporin-S6 (IC50 = 17 nM) and again, dianthin-32 (IC50 = 7 nM), indicating that the efficacy of RIPs on
eukaryotic ribosomes is dependent on the RIP and species [58] (Table 2). This was further corroborated
by investigating the effect on T. brucei and L. infantum ribosomes where ricin, modeccin, viscumin,
volkensin, gelonin, momordin, mochin from M. cochinchinensis (Lour.) Spreng., bryodin, trichokirin and
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barley (Hordeum vulgare L.) RIP had no or only very week effects (IC50 > 1.2 µM) while abrin, PAP-S,
PAP-R, saporin-S6, saporin-S9 as well as dianthin-30 and dianthin-32 had strong effects, the IC50 ranging
from 153 nM down to 5 nM [56]. It is notable that different publications describe RIP isolates from
M. cochinchinensis (Lour.) Spreng. that are called mochin, momochin, momorchin and momorcochin.
As sequence data are missing in most of the publications, it remains unclear whether these names
describe identical RIPs or isoenzymes. Indeed, in many cases, it is even unclear whether the isolate
is a uniform protein. Taylor et al. investigated the rRNA depurination activities of five RIPs using
yeast and tobacco leaf ribosomes. PAP-L, dianthin-32, tritin from wheat (Triticum aestivum L.) germ,
H. vulgare L. RIP and ricin A-chain were all active on yeast ribosomes with dianthin-32 being the most
active (IC50 = 0.019 nM) but only dianthin-32 (IC50 = 0.63 nM), PAP (IC50 = 0.13 nM) and ricin A chain
(IC50 = 20.8 nM) were active on tobacco ribosomes [52] (Table 2).
The enzymatic activity of RIPs is not highly specific for 28S rRNA. Other nucleic acids including
plasmids, herring sperm DNA (hsDNA), poly(A) and bacterial rRNA might also be recognized as substrate
by a number of RIPs [62]. Hartley and co-workers showed that bacterial 23S rRNA can be deadenylated by
the type 1 RIPs dianthin-30, dianthin-32, PAP-L and PAP-S but not by the A-chains of the type 2 RIPs ricin
and abrin [34]. This was proven by the release of a fragment of 243 nucleotides from the 3′ end of 23S
rRNA following aniline treatment of the RNA [34]. It is known that deadenylation renders the surrounding
phosphodiester bonds highly susceptible to hydrolysis after treatment with aniline [9,10]. The position of
deadenylation by dianthin-32 was found to be A-2660, which lies in a sequence that is highly conserved in all
species [34]. Roncuzzi and Gasperi-Campani described a DNA-nuclease activity for dianthin-30, saporin-S6
and gelonin in addition to the N-glycosidase activity [63]. In double-stranded, supercoiled pBR322 plasmid
DNA, they identified four cleavage sites for dianthin-30 and saporin-S6, and two cleavage sites for gelonin,
while ricin did not show any nuclease effect [63]. It is questionable whether the observed DNase activity
is indeed present. Instead, the phenomenon might be rather a consequence of an N-glycosidase activity,
which alters the torsional stress of the supercoiled DNA with subsequent break of the DNA strand [64].
Topologically active dianthin-30 and dianthin-32 was also observed for other plasmids including pGEM4Z
and pBlueScript SK+ [45,65,66].
The recognition of other substrates can be used to determine the catalytic activity of dianthin
directly instead of using indirect effects in translation assays. The principle of all these assays is to
determine the amount of adenine released in the presence of the enzyme. Heisler and colleagues
developed a colorimetric assay that is conducted in a single multi-reaction incubation step and
allows enzyme kinetic measurements [67]. The key step is the conversion of released adenine to
adenosine monophosphate by adenine phosphoribosyl transferase. Subsequent reactions finally result
in three inorganic phosphate ions per adenine molecule that are quantitated by a color-generating
phosphorolysis reaction [67]. The activity for dianthin-30 was determined for the 60S ribosomal
subunit, 28S-rRNA, mitochondrial DNA (mtDNA), hsDNA and poly(A). Compared to ricin A-chain
and saporin-S3 (which is almost identical to saporin-S6 [21]), the adenine release was highest for
dianthin-30 when using mtDNA and hsDNA as substrate, the maximum value reached for hsDNA
with 775 picomoles adenine release per picomole of RIP per hour of incubation while ricin A-chain was
the most active RIP on 28S-rRNA, exhibiting a release of 185 pmol/pmol/h [67] (Table 3). In this article,
the enzymatic activity of a RIP is always expressed as picomoles adenine release per picomole of RIP
per hour of incubation (pmol/pmol/h). If other units were used in the literature sources, magnitude and
unit were converted accordingly. For more clarity of the unit, we did not reduce the unit fraction to h–1,
which would be correct but more indistinct. For all three RIPs, the release was below the detection
limit of 10 pmol/pmol/h when using the 60S subunit or poly(A) as substrate. Fermani and co-workers
quantified released adenine by HPLC/MS ESI [43]. Using this sensitive method, they measured
a release of 0.39 to 0.72 pmol/pmol/h for dianthin-30, lychnin, momordin I, ricin A-chain, bouganin,
and PAP from rat ribosomes while saporin-S6 was most active exhibiting a release of 1.91 pmol/pmol/h.
Adenine release from hsDNA was an order of magnitude higher for dianthin-30, saporin-S6, bouganin
and PAP compared to lychnin, momordin-I and ricin A-chain [43], corroborating the results from Heisler
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and colleagues. Adenine release from poly(A) was only detectable for dianthin-30 (0.54 pmol/pmol/h)
and saporin-S6 (>30 pmol/pmol/h) [43]. Weng successfully applied a poly(dA) 30mer and detected
released adenine by thin-layer chromatography (TLC) and TLC-densitometry measuring UV absorbance
at 260 nm. For the optimization of the assay, deoxy-adenine oligonucleotides with different lengths
were used [68]. The release from the poly(dA) 30mer was substantially better than from an RNA
that mimics the ribosomal sarcin loop and determined to 110 pmol/pmol/h for dianthin-30 [68]. It is
unclear why the strikingly low activity of dianthin-30 observed by Fermani et al. and Heisler et al.
for poly(A) [43,67] compared to Weng is attributed to the defined length of 30 residues or to the
deoxynucleotides used by Weng. In another study where hsDNA was used as substrate, adenine
release by saporin-S3 was 10-fold higher than observed by Fermani et al. for saporin-S6, and 5-fold
higher for ricin A-chain [69].
Lubelli et al. described an immuno-polymerase chain reaction assay to detect dianthin and
ricin, a method suitable to quantify low amounts of these RIPs (down to 0.01 pg/mL) independent
of their enzymatic activity [70]. In this assay, dianthin was detected with a primary and secondary
biotin-labelled antibody, and a biotinylated reporter DNA was bound to the secondary antibody using
streptavidin as a bridge. Quantitation occurred by polymerase chain reaction of the reporter [70].
Table 3. Enzymatic activity of dianthin-30 and dianthin-30 derivates in comparison to other RIPs.
As in Table 2, the experimental conditions vary from study to study. Adenine release is indicated as
picomoles adenine released from the indicated substrate per picomole of RIP in one hour. Most of the
data result from end point measurements so that kinetic effects such as substrate depletion might have
affected the final outcome.







0.57 rat ribosomes [43]
<10 1 60S ribosomal subunit [67]
<10 1 poly(A) [67]
23.99 herring sperm DNA [43]
67 1 herring sperm DNA [71]
110 1 (dA)30 [68]
140 1 28S-rRNA [67]
330 1 mitochondrial DNA [67]
644 herring sperm DNA [72]
775 1 herring sperm DNA [67]
dianthin-30-EGF 3
42 1 herring sperm DNA [71]
67 1 (dA)30 [68]
116 1 herring sperm DNA [73]
218 1 herring sperm DNA [69]
dianthin-30-anti-CD30 4
247 1 herring sperm DNA [72]
346 herring sperm DNA [72]
saporin-S3
<10 1 60S ribosomal subunit [67]
<10 1 poly(A) [67]
50 1 mitochondrial DNA [67]
125 1 (dA)30 [68]
140 1 28S-rRNA [67]
312 1 herring sperm DNA [69]
397 herring sperm DNA [69]
670 1 herring sperm DNA [67]
saporin-S3-EGF 3
70 1 (dA)30 [68]
80 1 herring sperm DNA [73]
240 1 herring sperm DNA [69]
saporin-S6
1.91 rat ribosomes [43]
18.3 herring sperm DNA [74]
>30 poly(A) [43]
37.61 herring sperm DNA [43]
439 1 herring sperm DNA [72]
saporin-S6-anti-CD30 4 176 herring sperm DNA [72]
saporin-L1 861 herring sperm DNA [72]
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saporin-L1-anti-CD30 4 429 herring sperm DNA [72]
saporin-L2 934 herring sperm DNA [74]
PAP-S 519 herring sperm DNA [72]
PAP-S-anti-CD22 4 115 herring sperm DNA [72]
PAP-R
<d. l. 2 poly(A) [43]
0.51 rat ribosomes [43]
50.32 herring sperm DNA [43]
gelonin 12.9 herring sperm DNA [74]
579 herring sperm DNA [72]
gelonin-anti-CD30 4 130 herring sperm DNA [72]
momordin
<d. l. 2 poly(A) [43]
0.39 rat ribosomes [43]
0.75 herring sperm DNA [74]
2.71 herring sperm DNA [43]
18 herring sperm DNA [72]
momordin-anti-CD30 4 1.8 herring sperm DNA [72]
lychnin
<d. l. 2 poly(A) [43]
0.72 rat ribosomes [43]
2.95 herring sperm DNA [43]
bouganin
<d. l. 2 poly(A) [43]
0.48 rat ribosomes [43]
37.77 herring sperm DNA [43]
ricin A chain
<d. l. 2 poly(A) [43]
0.62 rat ribosomes [43]
4.85 herring sperm DNA [43]
<10 60S ribosomal subunit [67]
<10 poly(A) [67]
22 herring sperm DNA [69]
27.6 1 herring sperm DNA [72]
43 herring sperm DNA [67]
185 28S-rRNA [67]
ricin A chain-EGF 3 17 1 herring sperm DNA [69]
ricin A chain-anti-CD30 4 7.2 1 herring sperm DNA [72]
ricin
7.5 herring sperm DNA [74]
<10 mitochondrial DNA [67]
<10 60S ribosomal subunit [67]
12 28S-rRNA [67]
70 herring sperm DNA [67]
1 Recombinant RIP. 2 Less than detection limit. 3 EGF, epidermal growth factor. 4 CD, cluster of differentiation.
As early as 1925, Duggar described the anti-viral effect of pokeweed juice on tobacco plants
affected with the tobacco mosaic virus [75]. The active protein was isolated in 1969 [76] and the effect
on the larger ribosomal subunit was shown in 1973 [77]. The abbreviation PAP originally stood for
P. americana L. peptide but was later used as pokeweed antiviral protein. Stirpe et al. first described the
antiviral effect of dianthins [1]. The authors infected tobacco leaves with the tobacco-mosaic virus in
the presence and absence of dianthin-30 and dianthin-32 and observed almost complete inhibition
of virus-mediated lesions at 300 nM [1] (Table 4). This was confirmed by Taylor and colleagues who
observed that PAP and dianthin-32 fully inhibit the formation of local lesions at 300 and 3000 nM and
more than 80% at 30 nM and 60 nM, whereas tritin, H. vulgare L. RIP and ricin A-chain were essentially
ineffective [52]. Foà-Tomasi et al. infected HEp-2 cells with herpes simplex virus-1 (HSV-1) or with
poliovirus-I in the presence of dianthin-32, PAP-S, gelonin, and a RIP from the seeds of M. charantia.
All proteins investigated reduced the viral yield, decreased HSV-1 plaque-forming efficiency (Table 4),
and inhibited protein synthesis more in infected than in uninfected cells, presumably caused by entering
infected cells more easily [78]. As expected, the potency of RIPs on protein synthesis in cells is not the
same as in cell-free systems. In the latter, PAP-S, M. charantia inhibitor, dianthin-32 and gelonin act in
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a decreasing order of efficacy whereas in both uninfected and virus-infected HEp-2 cells, dianthin-32
and PAP-S are more potent than the M. charantia inhibitor and gelonin, demonstrating that other factors
are involved in cells, such as the rate of RIP penetration and degradation [78]. This is undergirded by
the observation that binding and uptake of saporin-S6 and momordin by choriocarcinoma BeWo and
cervical carcinoma HeLa cells are not correlated to cell toxicity [79]. Batelli and co-workers determined
the IC50 for inhibition of cell protein synthesis by dianthin-32, saporin-S6, bryodin-R, momordin,
gelonin and PAP-S on different cell lines and showed that human trophoblasts and BeWo cells are most
sensitive while human embryonal fibroblasts, choriocarcinoma JAR cells and ovarian carcinoma TG
cells were less affected. In particular, on fibroblasts, the efficacy of dianthin-32 and saporin-S6 was
better than that of the other tested RIPs [79].
Table 4. Effect of dianthin-30, dianthin-32 and other RIPs on virus-infected cells. Readout was the
inhibition of plaque formation caused by infected cells or the inhibition of lesion formation in tobacco
leaves (Nicotiana spec.).
RIP Concentration (µg/mL) Virus 1 Target Inhibition(%) Reference
dianthin-30
0.5 TMV N. glutinosa L. 63 [1]
1 TMV N. glutinosa L. 91 [1]
5 TMV N. glutinosa L. 96 [1]
10 TMV N. glutinosa L. 99 [1]
dianthin-32
0.01 TMV N. tabacum L. 0 [52]
0.05 TMV N. tabacum L. 0 [52]
0.1 TMV N. tabacum L. 57 [52]
0.5 TMV N. tabacum L. 76 [52]
0.5 TMV N. glutinosa L. 33 [1]
1 TMV N. tabacum L. 91 [52]
1 TMV N. glutinosa L. 84 [1]
2 TMV N. tabacum L. 91 [52]
5 TMV N. glutinosa L. 86 [1]
10 TMV N. tabacum L. 100 [52]
10 TMV N. glutinosa L. 98 [1]
100 TMV N. tabacum L. 100 [52]
100 HSV-1 HEp-2 cells 77 [78]
200 HSV-1 HEp-2 cells 85 [78]
PAP
0.01 TMV N. tabacum L. 0 [52]
0.05 TMV N. tabacum L. 0 [52]
0.1 TMV N. tabacum L. 57 [52]
0.5 TMV N. tabacum L. 76 [52]
1 TMV N. tabacum L. 91 [52]
2 TMV N. tabacum L. 91 [52]
10 TMV N. tabacum L. 100 [52]
100 TMV N. tabacum L. 100 [52]
PAP-S
100 HSV-1 HEp-2 cells 81 [78]
200 HSV-1 HEp-2 cells 90 [78]
gelonin 100 HSV-1 HEp-2 cells 31 [78]
200 HSV-1 HEp-2 cells 83 [78]
momordin
100 HSV-1 HEp-2 cells 70 [78]
200 HSV-1 HEp-2 cells 81 [78]
tritin
10 TMV N. tabacum L. 36 [52]
100 TMV N. tabacum L. 23 [52]
barley RIP 10 TMV N. tabacum L. 33 [52]
100 TMV N. tabacum L. 16 [52]
ricin A-chain
10 TMV N. tabacum L. 20 [52]
100 TMV N. tabacum L. 25 [52]
1 TMV, tobacco-mosaic virus; HSV-1, herpes simplex virus-1.
A strategy how plants can defend themselves against viruses was experimentally demonstrated by
Hong et al. by applying the dianthin-30 coding sequence including the N-terminal 23 amino acid signal
peptide to engineer resistance to the African cassava mosaic virus in the transgenic tobacco species
Nicotiana benthamiana Domin by using a promoter that is transactivated by a viral gene product [80].
When challenged with the virus, transgenic plants produced atypical necrotic lesions on inoculated
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leaves, indicating dianthin-30 expression, moreover, viral DNA accumulation was significantly reduced,
and plants exhibit attenuated systemic symptoms from which they recover [80]. By using a potato virus
X vector to express the transactivator protein from the African cassava mosaic virus directly in plants,
the authors confirmed that amplification of dianthin-30 activity in transgenic plants is indeed mediated
by the viral gene product [81]. When dianthin-30 is constitutively expressed in Nicotiana tabacum L. cv.
Wisconsin 38, the plants are not able to survive, however, dianthin-30 does not hamper the development
of rice (Oryza sativa L. subsp. indica cv. Pusa Basmati1) although all transgenic rice plants harbored
and expressed the complete dianthin-30 gene [82]. Notably, the transgenic lines showed reduction of
sheath blight symptoms in the range of 29 to 42% [82].
3. Dianthin Conjugates and Fusion Proteins
In the last decades, new targeted tumor therapies were developed in the battle against cancer.
Such therapies block the growth of cancer cells by interfering with specific pathways required for
carcinogenesis and tumor growth. Some procedures are targeted at certain enzymes, proteins, or other
molecules involved in the growth and spread of cancer cells and others support the immune system to
kill cancer cells or deliver toxic substances to cancer cells. The latter is characterized by a target specific
ligand, such as an antibody, growth factor or lectin, and a toxic moiety including radioisotopes, small
molecule drugs or protein toxins. Both parts can be conjugated chemically or in the case of proteins,
genetically fused [83]. Targeted toxins that contain an antibody or fragment thereof as a ligand are also
called immunotoxins.
As type 2 RIPs in addition to the catalytic domain possess a cell binding domain, a number of
these proteins are highly cytotoxic for regular cells, in particular, ricin. In contrast, type 1 RIPs such
as dianthin, saporin, gelonin, or agrostin from Agrostemma githago L. are better suited for the design
of targeted toxins since these toxins possess relatively low cytotoxic potential but can be coupled
to a targeting moiety to mediate cancer cell binding, internalization and subsequent cell death [17].
Indeed, the median lethal dose in mice after intraperitoneal injection was relatively high for dianthin-30
(12–16 mg/kg) and dianthin-32 (42–46 mg/kg) [46] compared to ricin (0.0024–0.036 mg/kg) [84].
Bolognesi et al. compared anti-lymphocyte immunotoxins containing different RIPs [57].
Immunotoxins were prepared by chemical cross-linking to the F(ab’)2 fragment of sheep anti-mouse IgG,
their inhibitory effect measured on cell free protein synthesis, and the cytotoxic activity tested on human
lymphocytes pretreated with an anti-cluster of differentiation (CD)3 murine monoclonal antibody [57].
Protein synthesis was inhibited by dianthin-32, saporin, PAP-S, gelonin, bryodin, momorcochin,
momordin, trichokirin, and ricin A-chain with IC50 values between 0.033 nM (saporin) and 0.40 nM
(gelonin), dianthin-32 showing an IC50 of 0.12 nM. As expected, the corresponding immunotoxins
exhibited reduced activity with IC50 values between 0.086 nM (saporin-F(ab’)2) and 6.2 nM
(gelonin-F(ab’)2) with the lowest reduction for ricin A-chain-F(ab’)2 (1.2-fold) and the highest reduction
for gelonin-F(ab’)2 (15.5-fold) [57] (Table 2). The activity for dianthin-32-F(ab’)2 was reduced 1.4-fold
to IC50 = 0.167 nM. The immunotoxins inhibited DNA synthesis in phytohemagglutinin-stimulated
lymphocytes with IC50 values ranging from 0.0026 nM (PAP-S-F(ab’)2) to 10 nM (gelonin-F(ab’)2),
demonstrating that the efficacy on cell free protein syntheses does not correlate with the activity
on cells (as PAP-S-F(ab’)2 was only the seventh best in blocking protein synthesis) [57] (Table 5).
Dianthin-32-F(ab’)2 was, after PAP-S-F(ab’)2 and saporin-F(ab’)2, the third most effective immunotoxin
(IC50 = 0.011 nM) [57]. In a second study, the authors tested anti-CD30 immunotoxins consisting of
a monoclonal antibody chemically coupled to native and recombinant dianthin-30 [54]. Native and
recombinant dianthin-30 inhibited cell-free protein synthesis with IC50 values of 0.133 nM and
0.227 nM, respectively. For the corresponding immunotoxins, the IC50 only increased for recombinant
dianthin-30-anti-CD30 (1.054 nM) [54]. Neither native nor recombinant dianthin-30 showed a toxic
effect at concentrations up to 10 nM on the CD30 positive cell lines D430B (lymphoblastoid), L428, L540
(both from Hodgkin’s lymphoma) and K562 (myelogenous leukemia). In contrast, both immunotoxins
selectively inhibited protein synthesis with IC50 values ranging from 0.324 nM to 0.479 nM for native
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dianthin-30-anti-CD30 and from 0.045 nM to 0.182 nM for recombinant dianthin-30-anti-CD30 on D430B,
L428 and L540 cells while K562 cells were not affected more than they were by free dianthin-30 [54]
(Table 5). The results demonstrated that dianthin-based targeted toxins can be effectively applied in
cell culture. IC50 values obtained in cell free assays are not a reliable predictor for cell-based assays.
The effect on cells can vary independently of the target receptor expression as other conditions including
endocytosis rate, recycling efficiency, degradation rate, endosomal release and toxin sensitivity might
also play a role.
Table 5. Cytotoxicity of dianthin-30 and dianthin-32 as well as derivates thereof in comparison to other
RIPs. Cells were incubated with different concentrations of the RIP. The toxin concentration resulting
in half maximal effect (IC50) was determined by readouts that differ between the studies.
RIP or RIP Fusion
Proteins/Conjugates Cytotoxicity IC50 (nM) Cells/Cell Line Reference
dianthin-30
>100 D430B [54]
>100 1 D430B [54]
~30 L540 [54]
~100 1 L540 [54]
>100 L428 [54]
~100 1 L428 [54]
712 1 Jurkat [55]
203 1,2 Jurkat [55]
910 H9 [46]
dianthin-30-EGF 3
0.45 1 HER14 4 [69]
<0.0000001 1,2 HER14 4 [69]
dianthin-30-anti-CD30 5
0.479 D430B [54]
0.162 1 D430B [54]
0.324 L540 [54]
0.045 1 L540 [54]
0.355 L428 [54]
0.182 1 L428 [54]
7.6 K562 [54]
>50 1 K562 [54]
dianthin-30-cetuximab
>10 1 HCT-116 [13]
0.0053 1,2 HCT-116 [13]
dianthin-30-panitumumab >10
1 HCT-116 [13]
0.0015 1,2 HCT-116 [13]
dianthin-30-trastuzumab
>10 1 BT-474 [13]
0.023 1,2 BT-474 [13]
dianthin-30-mAb2C4
10–20 SB2b [85]
0.01 2 SB2b [85]
0.01 2 JK2 [85]
0.02 2 U87MG [85]
transferrin-dianthin-30
1.5 1 Jurkat [55]
0.018 1,2 Jurkat [55]
KFT25-dianthin-30 6
>1000 1 Jurkat [55]
712 1,2 Jurkat [55]
pHA2-dianthin-30 6
>1000 1 Jurkat [55]
610 1,2 Jurkat [55]
pJVE-dianthin-30 6
814 1 Jurkat [55]
183 1,2 Jurkat [55]
dianthin-32 >3200 H9 [46]
dianthin-32-F(ab’)2 0.011 PBMC 7 [57]
saporin-S3
611 1 HeLa [86]
0.24 1,2 HeLa [86]
>1000 1 CaSki [86]
0.26 1,2 CaSki [86]
53 1 HER14 4 [86]
0.08 1,2 HER14 4 [86]
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Table 5. Cont.
RIP or RIP Fusion
Proteins/Conjugates Cytotoxicity IC50 (nM) Cells/Cell Line Reference
saporin-S3-EGF 3
53 1 HeLa [86]
0.00070 1,2 HeLa [86]
5 1 CaSki [86]
0.00013 1,2 CaSki [86]
2.5 1 HER14 4 [86]
0.00090 1,2 HER14 4 [86]
57 1 HER14 4 [69]
<0.0000001 1,2 HER14 4 [69]
saporin-S6-F(ab’)2 0.0055 PBMC 7 [57]
PAP-S-F(ab’)2 0.0026 PBMC 7 [57]
gelonin-mAb2C4 0.02 2 U87MG [85]
gelonin-F(ab’)2 10 PBMC 7 [57]
bryodin-F(ab’)2 0.0288 PBMC 7 [57]
momordin-F(ab’)2 0.02 PBMC 7 [57]
trichokirin-F(ab’)2 0.0323 PBMC 7 [57]
ricin A-chain
280 Jurkat [55]
140 2 Jurkat [55]
ricin A-chain-EGF 3
>1000 1 HER14 4 [69]
61 1,2 HER14 4 [69]
ricin A-chain-F(ab’)2 5 PBMC 7 [57]
1 Recombinant RIP. 2 In the presence of an endosomal escape enhancer. 3 EGF, epidermal growth factor. 4 HER14,
Swiss mouse embryo NIH-3T3 cells transfected with human EGFR. 5 CD, cluster of differentiation. 6 KFT25,
N-terminus of protein G of the vesicular stomatitis virus [59]; pHA2, N-terminus of the HA2 hemagglutinin of
influenza virus [60]; pJVE, proper name of a synthetic peptide [61]. 7 PBMC, peripheral blood mononuclear cells.
Barbieri and colleagues corroborated the diversity of affecting parameters on the efficacy of
RIPs [72]. They investigated immunotoxins comprising an anti-CD30 antibody and dianthin-30 (native
and recombinant), gelonin, momordin, PAP-S, PD-S2 from P. dioica L. leaves, saporin-L1, saporin-S6 or
ricin A-chain with regard to enzymatic activity (release of adenine from hsDNA, Table 3), inhibition
of cell-free translation and cytotoxicity on L540 cells, and in particular, investigated the effect of the
disulfide bonds arising from chemical conjugation. The authors showed that all immunotoxins act on
hsDNA and that the activity on hsDNA is only slightly affected by disulfide linkage to the antibody as
reduction of these bonds did not substantially increase the activity (only 1- to 6-fold) while inhibition of
cell-free protein translation is strongly affected (10- to 63-fold) [72]. The authors further observed that
the specific cytotoxicity of the immunotoxins does not correlate with substrate specificity. Among the
examined immunotoxins, recombinant and native dianthin-30 were the most effective on L540 cells [72].
In another study, Gilabert-Oriol et al. determined the IC50 value of recombinant His-tagged dianthin-30
chemically coupled to a monoclonal anti-calcitonin receptor antibody to 10–20 nM on high-grade
glioma SB2b cells. A conjugate of the same antibody with the small molecule toxin monomethyl
auristatin E revealed a similar cytotoxicity (IC50 = 25.1 nM) [85] (Table 5).
In the case that both ligand and toxin are proteins, heterologous expression of a genetically
engineered fusion protein is also an option to produce targeted toxins. Compared to chemically
conjugated toxins, the advantage of such an approach is the uniformity of the product, however,
expression must be optimized from scratch for each new targeted toxin. Gilabert-Oriol and co-workers
expressed two targeted toxins as fusion proteins under identical expression conditions in E. coli,
however, the yield of a His-tagged dianthin-30 fusion protein with epidermal growth factor (EGF) was
nearly two-times higher than the yield for an analogous protein containing saporin-S3 instead
of dianthin-30 [87]. Nevertheless, their biological specific activity, monitored in real time by
impedance measurement in a cell culture assay on human EGF receptor expressing HER14 cells,
was almost equal. A structural comparison revealed five major differences, one resulting in a loop
(saporin-EGF) to β-strand (dianthin-EGF) conversion and another introducing a gap in saporin-EGF
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(after position 57) [87]. Codon usage and toxicity to bacteria were excluded as a cause for different
protein expression levels, i.e., minor structural differences might be responsible for the protection of
dianthin-EGF from bacterial proteases and therefore may serve as a lead to modify certain domains in
type 1 RIP-based targeted toxins [87]. These results were undergirded by Weng, who expressed the same
constructs and determined the enzymatic activity of dianthin-EGF and saporin-S3-EGF in an adenine
release assay with 67 and 70 pmol/pmol/h respectively, using a poly(dA) 30mer as substrate [68]
(Table 3). In another study, the release from hsDNA was 218 pmol/pmol/h for dianthin-EGF and
240 pmol/pmol/h for saporin-S3-EGF [69].
4. Endosomal Escape
In contrast to bacterial toxins such as Pseudomonas aeruginosa exotoxin A or plant type 2 RIPs such
as ricin, type 1 RIPs do not possess a mechanism for retrograde transport to the endoplasmic reticulum
(ER) and subsequent cytosolic entry via exploitation of the ER-associated degradation pathway [88].
Further, type 1 RIPs do not possess an acid-sensitive translocation mechanism that allows escape from
acidic vesicles, as shown for diphtheria toxin [88,89]. Although the cytotoxic effect of dianthin proves
that it is in principle able to reach the cytosol by unknown mechanisms, the efficiency of this endosomal
escape is rather low. Therefore, several ideas were investigated to overcome endosomal entrapment
and subsequent lysosomal degradation. One approach is the insertion of a cell penetrating peptide to
promote the endosomal escape. It was shown that such peptides can improve the anti-tumor activity
of saporin-based targeted toxins and concomitantly reduce side effects in mouse tumor models [90].
Another possibility to facilitate the endosomal escape after clathrin-mediated endocytosis is the
combined application of certain glycosylated triterpenoids purified from Gypsophila paniculata L. and
S. officinalis L. [91]. These saponins are able to dramatically augment the inhibition of tumor growth by
RIP-based targeted toxins in mice, even after 50-fold reduction of the dose [92].
Lorenzetti et al. produced three fusion proteins consisting of the dianthin-30 gene and DNA
fragments encoding for the cell penetrating peptides KFT25 (N-terminus of protein G of the vesicular
stomatitis virus), pHA2 (N-terminus of the HA2 hemagglutinin of influenza virus), and pJVE
(synthetic peptide) [55]. The fusion proteins retained almost full enzymatic activity in cell-free assays
with IC50 values of 0.41 nM (dianthin-30), 0.47 nM (KFT25-dianthin), 0.53 nM (pHA2-dianthin-30),
and 0.54 nM (pJVE-dianthin-30) (Table 2). Conjugates made by chemically cross-linking KFT25-dianthin
and pJVE-dianthin and human transferrin showed greater cell-killing efficiency on Jurkat cells than
conjugates of transferrin with wild-type dianthin, but the effect was rather low, namely 3.8-fold and
1.8-fold, respectively (Table 5) [55].
Weng and colleagues tested the effect of the endosomal escape enhancer saponin SA1641 isolated
from G. paniculata L. on the efficacy of dianthin-30-EGF and other fusion toxins [69]. Without SA1641,
they observed an IC50 of 0.45 nM for dianthin-30-EGF and 57 nM for saporin-S3-EGF while in the
presence of SA1641, the IC50 was tremendously decreased to less than 1 fM corresponding to a more
than million-fold enhancement in efficacy. In contrast, ricin A-chain-EGF was only enhanced 16-fold
and an enzymatically active P. aeruginosa exotoxin fragment fused to EGF was not enhanced at all,
indicating that intracellular routing to late endosomes is important for the endosomal escape enhancer
effect [69] (Table 5). Gilabert-Oriol et al. investigated the effect of another saponin, named SO1861
and isolated from S. officinalis L., on chemical conjugates of dianthin-30 with the antibodies cetuximab,
panitumumab and trastuzumab [13]. The three immunotoxins did not cause any cytotoxic effects at
concentrations up to 10 nM on target cells, however, in combination with SO1861, strong cytotoxicity
was observed in all cases with IC50 values of 0.0053 nM for dianthin-30-cetuximab and 0.0015 nM for
dianthin-30-panitumumab, both tested on EGF receptor overexpressing colorectal carcinoma HCT-116
cells, and 0.023 nM for dianthin-30-trastuzumab on HER2 overexpressing mammary gland ductal
carcinoma BT-474 cells (Table 5) [13]. In another study, SO1861 was combined with chemical conjugates
of dianthin-30 and a monoclonal anti-calcitonin receptor antibody and tested on high-grade glioma
cell lines SB2b, JK2 and U87MG, resulting in IC50 values of 0.01 nM, 0.01 nM and 0.02 nM [85] (Table 5).
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While a conjugate with gelonin showed identical results on U87MG cells, the efficacy of a conjugate with
the small molecule toxin monomethyl auristatin E was substantially lower (IC50 = 6.3 nM), indicating
that SO1861 is suitable to enhance the endosomal escape of RIPs but not of small molecules [85].
Further applications for endosomal escape enhancers can be opened by transferring the genes instead
of the proteins into cells. This has already been successfully shown for the saporin cDNA and might
also be an option for dianthin cDNA [93,94].
5. Mouse Tumor Models
In order to demonstrate the potential of dianthin for targeted tumor therapies, successful
application in mouse tumor models would be valuable. In animals, in addition, other aspects such as
distribution in the body, liberation, absorption, metabolization and excretion influence efficacy and
kinetics of targeted toxins and endosomal escape enhancers, and other aspects such as immunogenicity
come into play. At the moment, there are only few studies available. Endosomal escape enhancers
that are injected subcutaneously into the neck are rapidly distributed in the body. Already after
10 min, the highest concentration in the kidneys is reached and all other organs showed the peak
concentration after 10 to 30 min [95]. Approximately only 1% of the endosomal escape enhancers
were detected in the tumor during 10 to 240 min after injection while the remainder was observed
in the urine after 30 to 60 min [95]. The toxicity of endosomal escape enhancers is characterized by
a clear threshold. All animals treated with 10 mg/kg SO1861 died on the second day of the experiment,
while the majority of mice treated with 0.75–5 mg/kg SO1861 only exhibited mild alterations of the liver
(e.g., single cell necrosis) but no damage of spleen and kidneys [96]. With regard to dianthin, no toxic
effect was observed in mice after intraperitoneal injection of dianthin-32 at doses up to 30 mg/kg body
weight [1]. The median lethal dose was determined to be 42–46 mg/kg for dianthin-32 and 12–16 mg/kg
for dianthin-30 [46]. Immunogenicity is also an important aspect when using non-human proteins.
Strocchi et al. determined the antibody titers in the sera of rabbits immunized with different RIPs.
Saporin-S6 was the most immunogenic toxin and resulted in an 11-fold higher titer than dianthin-32
and 29-fold higher titer than bryodin, which was the RIP with the lowest titer among nine tested [25]
(Table 6).
Table 6. Antibody titer of dianthin-32 and other RIPs in the sera of rabbits immunized with RIPs,
according to Strocchi et al. [25].










His-tagged dianthin-30 genetically fused to EGF was tested in combination with SO1861 in a nude
mouse model with subcutaneous HCT-116 tumors [73]. A tumor volume reduction of 96% and complete
regression in three of four cases was observed for mice treated with 0.0175 mg/kg dianthin-30-EGF and
1.5 mg/kg SO1861. Histopathological analyses only showed low-grade toxic alterations of the liver
such as cytoplasmic degeneration or single cell necrosis [73]. In both placebo and verum, the lymphatic
spleen tissue revealed a follicular hyperplasia group, which can be ascribed to an immune response of
residual T cells to tumor formation. Pancreas and lung did not show any morphological alterations [73].
The same combination of dianthin-30-EGF and SO1861 was used for the treatment of pancreatic BxPC-3
cell carcinoma in nude mice [71]. Monotherapy with dianthin-30-EGF in the absence of SO1861 resulted
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on average in a 52% reduction of the tumor volume and no complete regression was observed (three
mice had retarded tumor growth and two had continuous tumor growth). However, in the presence of
SO1861, the tumor volume was reduced on average by 97% and four out of five mice showed complete
regression [71]. Complete blood count analysis did not show suspicious values with the exception of
increased platelet count. At the injection site of SO1861, skin hardening was noticed after two therapy
cycles, but no skin lesions were observed at the injection site and at the tumor site after six therapy
cycles, indicating recovery [71]. Further animal studies with dianthin as the active pharmaceutic agent
are required to corroborate its potential role as a cancer cell-killing protein in targeting tumor therapies.
6. Conclusions
Dianthin-30 and dianthin-32 are the best investigated dianthin enzymes with dianthin-30 being
the lead in the last decade. Three types of activity measurement can be distinguished, direct detection
of the enzymatic activity by quantitation of released adenine from various substrates, determination of
protein synthesis inhibition in a cell free system, and quantitation of cell viability in cell culture assays.
The activity for different RIPs does typically not correlate between the three methods as different
properties of the molecule affect the efficacy. Dianthin is a highly active enzyme but as a type 1 RIP, it
does not possess a cell binding domain and therefore exhibits low cytotoxicity. This makes dianthin
an attractive candidate for targeted tumor therapies as the toxin can be chemically coupled or genetically
fused to a ligand that recognizes tumor-specific receptors. Regrettably, most of the targeted dianthin
molecules that have been bound to the target receptor are degraded in lysosomes or recycled back
to the cell surface after internalization. Endosomal escape enhancers such as particular glycosylated
triterpenoids can substantially enhance the release into the cytosol and thus increase the cytotoxicity
for target cells by a thousand- up to more than a million-fold. Systematic cell culture experiments
provided evidence that dianthin appears to be suitable for targeted tumor therapies. Dianthin can be
expressed with higher yield as saporin and is presumably less immunogenic. First studies in mice
with targeted dianthin in the presence of endosomal escape enhancers demonstrated the vast potential
of this plant enzyme.
Author Contributions: The review article was conceptualized and written by H.F.
Funding: We acknowledge support from the German Research Foundation (DFG) and the Open Access Publication
Fund of Charité – Universitätsmedizin Berlin.
Conflicts of Interest: The author declares no conflict of interest.
References
1. Stirpe, F.; Williams, D.G.; Onyon, L.J.; Legg, R.F.; A Stevens, W. Dianthins, ribosome-damaging proteins with
anti-viral properties from Dianthus caryophyllus L. (carnation). Biochem. J. 1981, 195, 399–405. [CrossRef]
2. Prestle, J.; Hornung, E.; Schönfelder, M.; Mundry, K.-W. Mechanism and site of action of
a ribosome-inactivating protein type 1 from Dianthus barbatus which inactivates Escherichia coli ribosomes.
FEBS Lett. 1992, 297, 250–252. [CrossRef]
3. Wang, Y.-C.; Tan, N.-H.; Zhou, J.; Wu, H.-M. Cyclopeptides from dianthus superbus. Phytochemistry 1998,
49, 1453–1456. [CrossRef]
4. Hsieh, P.-W.; Chang, F.-R.; Wu, C.-C.; Wu, K.-Y.; Li, C.-M.; Chen, S.-L.; Wu, Y.-C. New Cytotoxic Cyclic
Peptides and Dianthramide from Dianthus superbus. J. Nat. Prod. 2004, 67, 1522–1527. [CrossRef]
5. Amso, Z.; Kowalczyk, R.; Park, Y.-E.; Watson, M.; Lin, J.-M.; Musson, D.S.; Cornish, J.; Brimble, M.A.
Synthesis and in vitro bone cell activity of analogues of the cyclohexapeptide dianthin G. Org. Biomol. Chem.
2016, 14, 6231–6243. [CrossRef] [PubMed]
6. Tong, Y.; Luo, J.-G.; Wang, R.; Wang, X.-B.; Kong, L.-Y. New cyclic peptides with osteoblastic proliferative
activity from Dianthus superbus. Bioorg. Med. Chem. Lett. 2012, 22, 1908–1911. [CrossRef] [PubMed]
7. Han, J.; Huang, M.; Wang, Z.; Zheng, Y.; Zeng, G.; He, W.; Tan, N. Cyclopentapeptides from Dianthus chinensis.
J. Pept. Sci. 2015, 21, 550–553. [CrossRef] [PubMed]
Toxins 2019, 11, 592 20 of 24
8. Zhang, S.; Amso, Z.; Rodriguez, L.M.D.L.; Kaur, H.; Brimble, M.A.; Rodriguez, L.M.D.L. Synthesis of Natural
Cyclopentapeptides Isolated from Dianthus chinensis. J. Nat. Prod. 2016, 79, 1769–1774. [CrossRef] [PubMed]
9. Endo, Y.; Mitsui, K.; Motizuki, M.; Tsurugi, K. The mechanism of action of ricin and related toxic lectins on
eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by
the toxins. J. Boil. Chem. 1987, 262, 5908–5912.
10. Endo, Y.; Tsurugi, K.; Lambert, J.M. The site of action of six different ribosome-inactivating proteins
from plants on eukaryotic ribosomes: The RNA N-glycosidase activity of the proteins. Biochem. Biophys.
Res. Commun. 1988, 150, 1032–1036. [CrossRef]
11. Cho, H.-J.; Lee, S.-J.; Kim, S.; Kim, B.-D. Isolation and Characterization of cDNAs Encoding Ribosome
Inactivating Protein from Dianthus sinensis L. Mol. Cells 2000, 10, 135–141. [CrossRef] [PubMed]
12. Ferreras, J.M.; Iglesias, R.; Barbieri, L.; Alegre, C.; Bolognesi, A.; Rojo, M.A.; Carbajales, M.L.;
Escarmis, C.; Girbes, T. Effects and molecular action of ribosome-inactivating proteins on ribosomes
from Streptomyces lividans. Biochim. Biophys. Acta (BBA) Gen. Subj. 1995, 1243, 85–93. [CrossRef]
13. Gilabert-Oriol, R.; Weng, A.; Trautner, A.; Weise, C.; Schmid, D.; Bhargava, C.; Niesler, N.; Wookey, P.J.;
Fuchs, H.; Thakur, M. Combinatorial approach to increase efficacy of Cetuximab, Panitumumab and
Trastuzumab by dianthin conjugation and co-application of SO1861. Biochem. Pharmacol. 2015, 97, 247–255.
[CrossRef] [PubMed]
14. Legname, G.; Fossati, G.; Monzini, N.; Gromo, G.; Marcucci, F.; Mascagni, P.; Modena, D. Heterologous expression,
purification, activity and conformational studies of different forms of dianthin 30. Biomed. Pept. Proteins Nucleic
Acids Struct. Synth. Boil. Act. 1995, 1, 61–68.
15. Girbés, T.; Barbieri, L.; Ferreras, M.; Arias, F.J.; Rojo, M.A.; Alegre, C.; Stirpe, F.; Iglesias, R.; Escarmis, C. Effects
of ribosome-inactivating proteins on Escherichia coli and Agrobacterium tumefaciens translation systems.
J. Bacteriol. 1993, 175, 6721–6724. [CrossRef] [PubMed]
16. Schrot, J.; Weng, A.; Melzig, M.F. Ribosome-Inactivating and Related Proteins. Toxins 2015, 7, 1556–1615.
[CrossRef]
17. Gilabert-Oriol, R.; Weng, A.; Von Mallinckrodt, B.; Melzig, M.F.; Fuchs, H.; Thakur, M.
Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail
with Tumor Specific Efficacy. Curr. Pharm. Des. 2014, 20, 6584–6643. [CrossRef]
18. Rust, A.; Partridge, L.J.; Davletov, B.; Hautbergue, G.M. The Use of Plant-Derived Ribosome Inactivating
Proteins in Immunotoxin Development: Past, Present and Future Generations. Toxins 2017, 9, 344. [CrossRef]
19. Bortolotti, M.; Bolognesi, A.; Polito, L. Bouganin, an Attractive Weapon for Immunotoxins. Toxins 2018,
10, 323. [CrossRef]
20. Polito, L.; Bortolotti, M.; Mercatelli, D.; Battelli, M.G.; Bolognesi, A. Saporin-S6: A Useful Tool in
Cancer Therapy. Toxins 2013, 5, 1698–1722. [CrossRef]
21. Fabbrini, M.S.; Rappocciolo, E.; Carpani, D.; Solinas, M.; Valsasina, B.; Breme, U.; Cavallaro, U.; Nykjaer, A.;
Rovida, E.; Legname, G.; et al. Characterization of a saporin isoform with lower ribosome-inhibiting activity.
Biochem. J. 1997, 322, 719–727. [CrossRef] [PubMed]
22. Olsnes, S.; Pihl, A. Different biological properties of the two constituent peptide chains of ricin a toxic protein
inhibiting protein synthesis. Biochemistry 1973, 12, 3121–3126. [CrossRef] [PubMed]
23. Falasca, A.; Gasperi-Campani, A.; Abbondanza, A.; Barbieri, L.; Stirpe, F. Properties of the
ribosome-inactivating proteins gelonin, Momordica charantia inhibitor, and dianthins. Biochem. J. 1982,
207, 505–509. [CrossRef] [PubMed]
24. Reisbig, R.R.; Bruland, Ø.S. Dianthin 30 and 32 from Dianthus caryophyllus: Two inhibitors of plant protein
synthesis and their tissue distribution. Arch. Biochem. Biophys. 1983, 224, 700–706. [CrossRef]
25. Strocchi, P.; Barbieri, L.; Stirpe, F. Immunological properties of ribosome-inactivating proteins and
a saporin immunotoxin. J. Immunol. Methods 1992, 155, 57–63. [CrossRef]
26. Di Maro, A.; Valbonesi, P.; Bolognesi, A.; Stirpe, F.; De Luca, P.; Gigliano, G.S.; Gaudio, L.; Bovi, P.D.;
Ferranti, P.; Malorni, A.; et al. Isolation and characterization of four type-1 ribosome-inactivating proteins,
with polynucleotide:adenosine glycosidase activity, from leaves of Phytolacca dioica L. Planta 1999, 208, 125–131.
[CrossRef]
27. Bolognesi, A.; Olivieri, F.; Battelli, M.G.; Barbieri, L.; Falasca, A.I.; Parente, A.; Blanco, F.V.; Stirpe, F.
Ribosome-Inactivating Proteins (RNA N-glycosidases) from the Seeds of Saponaria ocymoides and
Vaccaria pyramidata. JBIC J. Boil. Inorg. Chem. 1995, 228, 935–940. [CrossRef] [PubMed]
Toxins 2019, 11, 592 21 of 24
28. Bolognesi, A.; Polito, L.; Olivieri, F.; Valbonesi, P.; Barbieri, L.; Battelli, M.G.; Carusi, M.V.; Benvenuto, E.;
Del Vecchio Blanco, F.; Di Maro, A.; et al. New ribosome-inactivating proteins with polynucleotide:Adenosine
glycosidase and antiviral activities from Basella rubra L. And bougainvillea spectabilis willd. Planta 1997,
203, 422–429. [CrossRef]
29. Barbieri, L.; Polito, L.; Bolognesi, A.; Ciani, M.; Pelosi, E.; Farini, V.; Jha, A.; Sharma, N.; Vivanco, J.;
Chambery, A. Ribosome-inactivating proteins in edible plants and purification and characterization of a new
ribosome-inactivating protein from Cucurbita moschata. Biochim. Biophys. Acta (BBA) Gen. Subj. 2006,
1760, 783–792. [CrossRef]
30. Lappi, D.A.; Esch, F.S.; Barbieri, L.; Stirpe, F.; Soria, M. Characterization of a Saponaria officinalis seed
ribosome-inactivating protein: Immunoreactivity and sequence homologies. Biochem. Biophys. Res. Commun.
1985, 129, 934–942. [CrossRef]
31. Porro, G.; Bonardi, M.; Giovanetti, E.; Lento, P.; Modena, D. Production and Characterization of Monoclonal
Antibodies Against the Ribosome Inactivating Proteins Dianthin32 and Momochin. Hybridoma 1994,
13, 99–105. [CrossRef] [PubMed]
32. Szalai, K.; Schöll, I.; Polito, L.; Bolognesi, A.; Untersmayr, E.; Riemer, A.B.; Stirpe, F.; Forster-Waldl, E.;
Riemer, A.; Boltz-Nitulescu, G.; et al. Occupational sensitization to ribosome-inactivating proteins
in researchers. Clin. Exp. Allergy 2005, 35, 1354–1360. [CrossRef] [PubMed]
33. Legname, G.; Gromo, G.; Lord, J.; Monzini, N.; Modena, D. Expression and Activity of Pre-dianthin 30 and
Dianthin 30. Biochem. Biophys. Res. Commun. 1993, 192, 1230–1237. [CrossRef] [PubMed]
34. Hartley, M.R.; Legname, G.; Osborn, R.; Chen, Z.; Lord, J. Single-chain ribosome inactivating proteins from
plants depurinate Escherichia coli 23S ribosomal RNA. FEBS Lett. 1991, 290, 65–68. [CrossRef]
35. Legname, G.; Bellosta, P.; Gromo, G.; Modena, D.; Keen, J.N.; Roberts, L.M.; Lord, J.M. Nucleotide sequence
of cDNA coding for dianthin 30, a ribosome inactivating protein from Dianthus caryophyllus.
Biochim. Biophys. Acta (BBA) Gene Struct. Expr. 1991, 1090, 119–122. [CrossRef]
36. Kokorin, A.; Weise, C.; Sama, S.; Weng, A. A new type 1 ribosome-inactivating protein from the seeds of
Gypsophila elegans M.Bieb. Phytochemistry 2019, 157, 121–127. [CrossRef] [PubMed]
37. Bednarek, S.Y.; Wilkins, T.A.; Dombrowski, J.E.; Raikhel, N.V. A Carboxyl-Terminal Propeptide Is Necessary
for Proper Sorting of Barley Lectin to Vacuoles of Tobacco. Plant Cell 1990, 2, 1145. [PubMed]
38. Fermani, S.; Falini, G.; Ripamonti, A.; Polito, L.; Stirpe, F.; Bolognesi, A. The 1.4 anstroms structure of dianthin
30 indicates a role of surface potential at the active site of type 1 ribosome inactivating proteins. J. Struct. Biol.
2005, 149, 204–212. [CrossRef] [PubMed]
39. Madeira, F.; Park, Y.M.; Lee, J.; Buso, N.; Gur, T.; Madhusoodanan, N.; Basutkar, P.; Tivey, A.R.N.; Potter, S.C.;
Finn, R.D.; et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res. 2019,
47, W636–W641. [CrossRef]
40. Bravi, G.; Legname, G.; Chan, A. Substrate recognition by ribosome-inactivating protein studied by molecular
modeling and molecular electrostatic potentials. J. Mol. Graph. 1995, 13, 83–88. [CrossRef]
41. Kurinov, I.V.; Rajamohan, F.; Uckun, F.M. High resolution x-ray structure and potent anti-hiv activity of
recombinant dianthin antiviral protein. Arzneimittelforschung 2004, 54, 692–702. [CrossRef] [PubMed]
42. Fermani, S.; Falini, G.; Ripamonti, A.; Bolognesi, A.; Polito, L.; Stirpe, F. Crystallization and preliminary X-ray
diffraction analysis of two ribosome-inactivating proteins: Lychnin and dianthin 30. Acta Crystallogr. Sect.
D Boil. Crystallogr. 2003, 59, 1227–1229. [CrossRef] [PubMed]
43. Fermani, S.; Tosi, G.; Farini, V.; Polito, L.; Falini, G.; Ripamonti, A.; Barbieri, L.; Chambery, A.; Bolognesi, A.
Structure/function studies on two type 1 ribosome inactivating proteins: Bouganin and lychnin. J. Struct. Boil.
2009, 168, 278–287. [CrossRef] [PubMed]
44. Gawlak, S.L.; Neubauer, M.; Klei, H.E.; Chang; Einspahr, H.M.; Siegall, C.B. Molecular, Biological,
and Preliminary Structural Analysis of Recombinant Bryodin 1, a Ribosome-Inactivating Protein from
the PlantBryonia dioica. Biochemistry 1997, 36, 3095–3103. [CrossRef] [PubMed]
45. Chen, H.C.; Kung, H.F.; Huang, P.L.; I Huang, H.; Lee-Huang, S. Anti-HIV plant proteins catalyze topological
changes of DNA into inactive forms. BioFactors 1992, 4, 37–41.
46. Lee-Huang, S.; Kung, H.-F.; Huang, P.L.; Huang, P.L.; Li, B.-Q.; Huang, P.; Huang, H.I.; Chen, H.-C. A new
class of anti-HIV agents: GAP31, DAPs 30 and 32. FEBS Lett. 1991, 291, 139–144. [CrossRef]
47. Savino, C.; Federici, L.; Ippoliti, R.; Lendaro, E.; Tsernoglou, D. The crystal structure of saporin SO6 from
Saponaria officinalis and its interaction with the ribosome. FEBS Lett. 2000, 470, 239–243. [CrossRef]
Toxins 2019, 11, 592 22 of 24
48. Mlsna, D.; Monzingo, A.F.; Katzin, B.J.; Ernst, S.; Robertus, J.D. Structure of recombinant ricin a chain at 2.3 a.
Protein Sci. 1993, 2, 429–435. [CrossRef]
49. Xu, Y.-Z.; Liu, W.-Y. Effects of the Active Aldehyde Group Generated by RNA N-Glycosidase in the
Sarcin/Ricin Domain of Rat 28S Ribosomal RNA on Peptide Elongation. Boil. Chem. 2000, 381, 113–119.
[CrossRef]
50. Harley, S.M.; Beevers, H. Ricin inhibition of in vitro protein synthesis by plant ribosomes. Proc. Natl. Acad.
Sci. USA 1982, 79, 5935–5938. [CrossRef]
51. Lappi, D.A.; Ying, W.; Barthelemy, I.; Martineau, D.; Prieto, I.; Benatti, L.; Soria, M.; Baird, A. Expression
and activities of a recombinant basic fibroblast growth factor-saporin fusion protein. J. Boil. Chem. 1994,
269, 12552–12558.
52. Taylor, S.; Massiah, A.; Lomonossoff, G.; Roberts, L.M.; Lord, J.M.; Hartley, M. Correlation between the
activities of five ribosome-inactivating proteins in depurination of tobacco ribosomes and inhibition of
tobacco mosaic virus infection. Plant J. 1994, 5, 827–835. [CrossRef] [PubMed]
53. Zarovni, N.; Vago, R.; Solda, T.; Monaco, L.; Fabbrini, M.S. Saporin as a novel suicide gene in anticancer
gene therapy. Cancer Gene Ther. 2007, 14, 165–173. [CrossRef] [PubMed]
54. Bolognesi, A.; Tazzari, P.L.; Legname, G.; Olivieri, F.; Modena, D.; Conte, R.; Stirpe, F.; Legname, G. Anti-CD30
immunotoxins with native and recombinant dianthin 30. Cancer Immunol. Immunother. 1995, 40, 109–114.
[CrossRef] [PubMed]
55. Lorenzetti, I.; Meneguzzi, A.; Fracasso, G.; Potrich, C.; Costantini, L.; Chiesa, E.; Legname, G.; Menestrina, G.;
Tridente, G.; Colombatti, M. Genetic grafting of membrane-acting peptides to the cytotoxin dianthin
augments its ability to de-stabilize lipid bilayers and enhances its cytotoxic potential as the component of
transferrin-toxin conjugates. Int. J. Cancer 2000, 86, 582–589. [CrossRef]
56. Cenini, P.; Bolognesi, A.; Stirpe, F. Ribosome-inactivating proteins from plants inhibit ribosome activity of
Trypanosoma and Leishmania. J. Protozool. 1988, 35, 384–387. [CrossRef]
57. Bolognesi, A.; Tazzari, P.L.; Tassi, C.; Gromo, G.; Gobbi, M.; Stirpe, F. A comparison of anti-lymphocyte
immunotoxins containing different ribosome-inactivating proteins and antibodies. Clin. Exp. Immunol. 1992,
89, 341–346. [CrossRef]
58. Cenini, P.; Battelli, M.G.; Bolognesi, A.; Stirpe, F.; Villemez, C.L. Effect of ribosome-inactivating proteins on
ribosomes from Tetrahymena pyriformis and Acanthamoeba castellanii. Biochem. Biophys. Res. Commun. 1987,
148, 521–527. [CrossRef]
59. Schlegel, R.; Wade, M. A synthetic peptide corresponding to the NH2 terminus of vesicular stomatitis virus
glycoprotein is a pH-dependent hemolysin. J. Boil. Chem. 1984, 259, 4691–4694.
60. Wagner, E.; Plank, C.; Zatloukal, K.; Cotten, M.; Birnstiel, M.L. Influenza virus hemagglutinin HA-2
N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward
a synthetic virus-like gene-transfer vehicle. Proc. Natl. Acad. Sci. USA 1992, 89, 7934–7938. [CrossRef]
61. Pécheur, E.I.; Sainte-Marie, J.; Bienvene, A.; Hoekstra, D. Peptides and membrane fusion: Towards
an understanding of the molecular mechanism of protein-induced fusion. J. Membr. Biol. 1999, 167, 1–17.
[CrossRef] [PubMed]
62. Barbieri, L.; Gorini, P.; Valbonesi, P.; Castiglioni, P.; Stirpe, F. Unexpected activity of saporins. Nature 1994,
372, 624. [CrossRef] [PubMed]
63. Roncuzzi, L.; Gasperi-Campani, A. DNA-nuclease activity of the single-chain ribosome-inactivating proteins
dianthin 30, saporin 6 and gelonin. FEBS Lett. 1996, 392, 16–20. [CrossRef]
64. Panayotatos, N.; Wells, R.D. Cruciform structures in supercoiled DNA. Nature 1981, 289, 466–470. [CrossRef]
[PubMed]
65. De Benito, F.M.; Citores, L.; Iglesias, R.; Ferreras, J.; Camafeita, E.; Méndez, E.; Girbés, T. Isolation and partial
characterization of a novel and uncommon two-chain 64-kDa ribosome-inactivating protein from the bark of
elder (Sambucus nigra L.). FEBS Lett. 1997, 413, 85–91. [CrossRef]
66. De Benito, F.M.; Iglesias, R.; Ferreras, J.M.; Citores, L.; Camafeita, E.; Méndez, E.; Girbés, T. Constitutive and
inducible type 1 ribosome-inactivating proteins (RIPs) in elderberry (Sambucus nigra L.). FEBS Lett. 1998,
428, 75–79. [CrossRef]
67. Heisler, I.; Keller, J.; Tauber, R.; Sutherland, M.; Fuchs, H. A Colorimetric Assay for the Quantitation of Free
Adenine Applied to Determine the Enzymatic Activity of Ribosome-Inactivating Proteins. Anal. Biochem.
2002, 302, 114–122. [CrossRef] [PubMed]
Toxins 2019, 11, 592 23 of 24
68. Weng, A. A novel adenine-releasing assay for ribosome-inactivating proteins. J. Chromatogr. B 2018,
1072, 300–304. [CrossRef] [PubMed]
69. Weng, A.; Thakur, M.; Beceren-Braun, F.; Bachran, D.; Bachran, C.; Riese, S.B.; Jenett-Siems, K.;
Gilabert-Oriol, R.; Melzig, M.F.; Fuchs, H. The toxin component of targeted anti-tumor toxins determines
their efficacy increase by saponins. Mol. Oncol. 2012, 6, 323–332. [CrossRef] [PubMed]
70. Lubelli, C.; Chatgilialoglu, A.; Bolognesi, A.; Strocchi, P.; Colombatti, M.; Stirpe, F. Detection of ricin and
other ribosome-inactivating proteins by an immuno-polymerase chain reaction assay. Anal. Biochem. 2006,
355, 102–109. [CrossRef] [PubMed]
71. Bhargava, C.; Dürkop, H.; Zhao, X.; Weng, A.; Melzig, M.F.; Fuchs, H. Targeted dianthin is a powerful
toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene SO1861.
Mol. Oncol. 2017, 11, 1527–1543. [CrossRef] [PubMed]
72. Barbieri, L.; Bolognesi, A.; Valbonesi, P.; Polito, L.; Olivieri, F.; Stirpe, F. Polynucleotide: Adenosine
Glycosidase Activity of Immunotoxins Containing Ribosome-Inactivating Proteins. J. Drug Target. 2000,
8, 281–288. [CrossRef] [PubMed]
73. Von Mallinckrodt, B.; Thakur, M.; Weng, A.; Gilabert-Oriol, R.; Dürkop, H.; Brenner, W.; Lukas, M.;
Beindorff, N.; Melzig, M.F.; Fuchs, H. Dianthin-EGF is an effective tumor targeted toxin in combination with
saponins in a xenograft model for colon carcinoma. Futur. Oncol. 2014, 10, 2161–2175. [CrossRef] [PubMed]
74. Barbieri, L.; Brigotti, M.; Perocco, P.; Carnicelli, D.; Ciani, M.; Mercatali, L.; Stirpe, F. Ribosome-inactivating
proteins depurinate poly(ADP-ribosyl)ated poly(ADP-ribose) polymerase and have transforming activity
for 3T3 fibroblasts. FEBS Lett. 2003, 538, 178–182. [CrossRef]
75. Duggar, B.M.; Armstrong, J.K. The Effect of Treating the Virus of Tobacco Mosaic with the Juices of
Various Plants. Ann. Mol. Bot. Gard. 1925, 12, 359. [CrossRef]
76. Wyatt, S.D.; Shepherd, R.J. Isolation and characterization of a virus inhibitor from Phytolacca americana.
Phytopathology 1969, 59, 1787–1794. [PubMed]
77. Obrig, T.G.; Irvin, J.D.; Hardesty, B. The effect of an antiviral peptide on the ribosomal reactions of the peptide
elongation enzymes, EF-I and EF-II. Arch. Biochem. Biophys. 1973, 155, 278–289. [CrossRef]
78. Campadelli-Fiume, G.; Barbieri, L.; Stirpe, F.; Foà-Tomasi, L. Effect of ribosome-inactivating proteins on
virus-infected cells. Inhibition of virus multiplication and of protein synthesis. Arch. Virol. 1982, 71, 323–332.
79. Battelli, M.G.; Montacuti, V.; Stirpe, F. High sensitivity of cultured human trophoblasts to
ribosome-inactivating proteins. Exp. Cell Res. 1992, 201, 109–112. [CrossRef]
80. Hong, Y.; Saunders, K.; Hartley, M.R.; Stanley, J. Resistance to Geminivirus Infection by Virus-Induced
Expression of Dianthin in Transgenic Plants. Virology 1996, 220, 119–127. [CrossRef]
81. Hong, Y.; Saunders, K.; Stanley, J. Transactivation of Dianthin Transgene Expression by African Cassava
Mosaic Virus AC2. Virology 1997, 228, 383–387. [CrossRef] [PubMed]
82. Shah, J.M.; Veluthambi, K. DIANTHIN, a negative selection marker in tobacco, is non-toxic in transgenic rice
and confers sheath blight resistance. Boil. Plant. 2010, 54, 443–450. [CrossRef]
83. Polito, L.; Djemil, A.; Bortolotti, M. Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview.
Biomedicines 2016, 4, 12. [CrossRef] [PubMed]
84. Worbs, S.; Köhler, K.; Pauly, D.; Avondet, M.-A.; Schaer, M.; Dorner, M.B.; Dorner, B.G. Ricinus communis
Intoxications in Human and Veterinary Medicine-A Summary of Real Cases. Toxins 2011, 3, 1332–1372.
[CrossRef] [PubMed]
85. Gilabert-Oriol, R.; Furness, S.G.B.; Stringer, B.W.; Weng, A.; Fuchs, H.; Day, B.W.; Kourakis, A.; Boyd, A.W.;
Hare, D.L.; Thakur, M.; et al. Dianthin-30 or gelonin versus monomethyl auristatin e, each configured with
an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived
from glioblastoma. Cancer Immunol. Immunother. 2017, 66, 1217–1228. [CrossRef] [PubMed]
86. Bachran, D.; Schneider, S.; Bachran, C.; Urban, R.; Weng, A.; Melzig, M.F.; Hoffmann, C.; Kaufmann, A.M.;
Fuchs, H. Epidermal growth factor receptor expression affects the efficacy of the combined application
of saponin and a targeted toxin on human cervical carcinoma cells. Int. J. Cancer 2010, 127, 1453–1461.
[CrossRef]
87. Gilabert-Oriol, R.; Thakur, M.; Weise, C.; Dernedde, J.; Von Mallinckrodt, B.; Fuchs, H.; Weng, A.
Small structural differences of targeted anti-tumor toxins result in strong variation of protein expression.
Protein Expr. Purif. 2013, 91, 54–60. [CrossRef]
Toxins 2019, 11, 592 24 of 24
88. Vago, R.; Marsden, C.J.; Lord, J.M.; Ippoliti, R.; Flavell, D.J.; Flavell, S.-U.; Ceriotti, A.; Fabbrini, M.S.
Saporin and ricin A chain follow different intracellular routes to enter the cytosol of intoxicated cells. FEBS J.
2005, 272, 4983–4995. [CrossRef]
89. Kaul, P.; Silverman, J.; Shen, W.H.; Blanke, S.R.; Huynh, P.D.; Finkelstein, A.; Collier, R.J. Roles of glu 349 and
asp 352 in membrane insertion and translocation by diphtheria toxin. Protein Sci. 1996, 5, 687–692. [CrossRef]
90. Fuchs, H.; Bachran, C.; Li, T.; Heisler, I.; Dürkop, H.; Sutherland, M. A cleavable molecular adapter
reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice.
J. Control. Release 2007, 117, 342–350. [CrossRef]
91. Fuchs, H.; Niesler, N.; Trautner, A.; Sama, S.; Jerz, G.; Panjideh, H.; Weng, A. Glycosylated Triterpenoids as
Endosomal Escape Enhancers in Targeted Tumor Therapies. Biomedicines 2017, 5, 14. [CrossRef] [PubMed]
92. Bachran, C.; Dürkop, H.; Sutherland, M.; Bachran, D.; Müller, C.; Weng, A.; Melzig, M.F.; Fuchs, H.
Inhibition of Tumor Growth by Targeted Toxins in Mice is Dramatically Improved by Saponinum Album in
a Synergistic Way. J. Immunother. 2009, 32, 713–725. [CrossRef] [PubMed]
93. Sama, S.; Jerz, G.; Thakur, M.; Melzig, M.F.; Weng, A. Structure-Activity Relationship of
Transfection-Modulating Saponins—A Pursuit for the Optimal Gene Trafficker. Planta Med. 2019, 85, 513–518.
[CrossRef] [PubMed]
94. Sama, S.; Woith, E.; Walther, W.; Jerz, G.; Chen, W.; Hart, S.; Melzig, M.F.; Weng, A. Targeted suicide gene
transfections reveal promising results in nu/nu mice with aggressive neuroblastoma. J. Control. Release 2018,
275, 208–216. [CrossRef] [PubMed]
95. Bachran, C.; Weng, A.; Bachran, D.; Riese, S.B.; Schellmann, N.; Melzig, M.F.; Fuchs, H. The distribution of
saponins in vivo affects their synergy with chimeric toxins against tumours expressing human epidermal
growth factor receptors in mice. Br. J. Pharmacol. 2010, 159, 345–352. [CrossRef] [PubMed]
96. Thakur, M.; Mergel, K.; Weng, A.; von Mallinckrodt, B.; Gilabert-Oriol, R.; Durkop, H.; Melzig, M.F.; Fuchs, H.
Targeted tumor therapy by epidermal growth factor appended toxin and purified saponin: An evaluation of
toxicity and therapeutic potential in syngeneic tumor bearing mice. Mol. Oncol. 2013, 7, 475–483. [CrossRef]
[PubMed]
© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
